Shota Yamashita, Masayuki Kanamori, Yoshiteru Shimoda, Yoshinari Osada, Mika Watanabe, Rei Umezawa et al. CDKN2A/B status and histological grade independently predict post-recurrence survival in recurrent IDH-mutant astrocytoma. // Brain Tumor Pathology. – 2026. – DOI: 10.1007/s10014-026-00541-7. – URL: https://doi.org/10.1007/s10014-026-00541-7
Shota Yamashita, Masayuki Kanamori, Yoshiteru Shimoda, Yoshinari Osada, Mika Watanabe, Rei Umezawa, Keiichi Jingu, Ichiyo Shibahara, Ryuta Saito, Yukihiko Sonoda, Toshihiro Kumabe, & Hidenori Endo (2026). CDKN2A/B status and histological grade independently predict post-recurrence survival in recurrent IDH-mutant astrocytoma. Brain Tumor Pathology. https://doi.org/10.1007/s10014-026-00541-7
Shota Yamashita, et al. “CDKN2A/B status and histological grade independently predict post-recurrence survival in recurrent IDH-mutant astrocytoma.” Brain Tumor Pathology, 2026. doi:10.1007/s10014-026-00541-7.
@article{Yamashita2026,
title = {CDKN2A/B status and histological grade independently predict post-recurrence survival in recurrent IDH-mutant astrocytoma},
author = {Yamashita, Shota and Kanamori, Masayuki and Shimoda, Yoshiteru and Osada, Yoshinari and Watanabe, Mika and Umezawa, Rei and Jingu, Keiichi and Shibahara, Ichiyo and Saito, Ryuta and Sonoda, Yukihiko and Kumabe, Toshihiro and Endo, Hidenori},
journal = {Brain Tumor Pathology},
year = {2026},
doi = {10.1007/s10014-026-00541-7},
url = {https://doi.org/10.1007/s10014-026-00541-7}
}